Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$485K Sell
1,927
-3
-0.2% -$645 0.04% 65
2026
Q1
$420K Buy
1,930
+46
+2% +$10.2K 0.04% 65
2025
Q4
$430K Sell
1,884
-15
-0.8% -$3.42K 0.03% 57
2025
Q3
$440K Sell
1,899
-14
-0.7% -$2.85K 0.04% 60
2025
Q2
$355K Buy
1,913
+29
+2% +$5.39K 0.03% 66
2025
Q1
$395K Buy
1,884
+5
+0.3% +$972 0.04% 64
2024
Q4
$334K Buy
1,879
+26
+1% +$4.78K 0.03% 72
2024
Q3
$366K Buy
1,853
+5
+0.3% +$933 0.04% 68
2024
Q2
$317K Buy
1,848
+11
+0.6% +$1.82K 0.03% 63
2024
Q1
$335K Sell
1,837
-8
-0.4% -$1.38K 0.04% 55
2023
Q4
$286K Buy
+1,845
New +$269K 0.04% 61
2023
Q2
Sell
-1,280
Closed -$204K 82
2023
Q1
$204K Sell
1,280
-331
-21% -$50.6K 0.03% 70
2022
Q4
$260K Hold
1,611
0.04% 55
2022
Q3
$216K Buy
1,611
+54
+3% +$7.75K 0.03% 65
2022
Q2
$238K Hold
1,557
0.04% 64
2022
Q1
$252K Sell
1,557
-215
-12% -$31.2K 0.03% 72
2021
Q4
$240K Buy
+1,772
New +$209K 0.03% 77

Other funds holding ABBV

J.L. Bainbridge & Co's ABBV Position: Q2 2026 in Review

J.L. Bainbridge & Co reduced its AbbVie (ABBV) stake by 0.16% in Q2 2026, selling an estimated $645 and leaving 1,927 shares worth $485K. The position accounts for 0.04% of the portfolio, ranked #65.

J.L. Bainbridge & Co first reported a position in ABBV in Q4 2021 and has held it in 17 quarters since. 2,220 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • J.L. Bainbridge & Co held 1,927 shares of AbbVie worth $485K as of Q2 2026.
  • J.L. Bainbridge & Co sold 3 AbbVie shares in Q2 2026, an estimated $645.
  • AbbVie made up 0.04% of J.L. Bainbridge & Co's portfolio in Q2 2026, its #65 holding.
  • J.L. Bainbridge & Co first reported a position in AbbVie in Q4 2021 and has held it in 17 quarters since.
  • 2,220 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on J.L. Bainbridge & Co's 13F filing for Q2 2026, filed 22 Jul 2026.